Mark Polizzotto is Professor of Medicine at The Australian National University John Curtin School of Medical Research, where he leads the Clinical Hub in Interventional Research (CHOIR), and Senior Staff Haematologist at The Canberra Hospital.
Mark is a clinical triallist with a focus to developing new therapies to prevent and treat infection-related cancers. Mark's work on viral and HIV-associated cancers has influenced guidelines globally, including co-leading development of an oral immunomodulator for Kaposi sarcoma which led to the first new drug approval for KS in over 20 years.
From 2017 to 2021 he was head of the Therapeutic Research Program at the Kirby Institute. During that time he led several international randomised trials in HIV, influenza, and COVID-19 infection in collaboration with the U.S. National Institutes of Health, the World Health Organization, Unitaid, and others. He also led capacity development efforts in clinical trials for the NIH in West Africa and Indonesia.
His has published in key journals in the fields of infection, immunity, and malignancy including Blood, the Journal of Clinical Oncology, Lancet journals, Nature Medicine, and the New England Journal of Medicine.